MSA Logo

MSA Trial Tracker

Browse active clinical trials for Multiple System Atrophy (MSA).

Tracker extracts data from ClinicalTrials.gov, a database managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in Bethesda, Maryland. This trial tracker is provided for informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider for all diagnosis questions or medical treatment before taking any action or making any decision regarding your health.

Understanding Clinical Trial Phases & Status (click to show/hide)

Phase 1: A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.

Phase 2: A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Phase 3: A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Phase 4: A phase of research to describe clinical trials occurring after the FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use.

Phase Not Applicable: Describes trials without FDA-defined phases, including trials of devices or behavioral interventions.

Understanding the Status of active studies:

Not yet recruiting: The study has not started recruiting participants.

Recruiting: The study is currently recruiting participants.

Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Filters
Phases
Sexes
Age
Country
Study ID Title Phase Status Start Date Completion
NCT05696717 Ampreloxetine Phase Three Active Jun 2023 Jan 2028
NCT06706622 Lu AF82422 Phase Three Active Dec 2024 Oct 2029
NCT05923866 ONO-2808 Phase Two Active Sep 2023 Jan 2027
NCT06568237 TEV-56286 Phase Two Active Recruiting Oct 2024 Sep 2027
NCT06671938 Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With MSA Phase Two Active Oct 2024 Aug 2026
NCT06848231 A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy Phase Two Active Recruiting Mar 2025 Dec 2026
NCT07197866 An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple Syst… Phase Two Active Recruiting Sep 2025 May 2029
NCT03482297 Abdominal Binder Phase One Active Recruiting Mar 2018 Dec 2024
NCT04165486 ION464 Phase One Active Recruiting Jul 2022 Sep 2027
NCT04680065 GDNF Gene Therapy Phase One Active Oct 2023 Aug 2028
NCT07446894 Phase III Trial of MSA-01 in Multiple System Atrophy Phase Three Active Recruiting Feb 2026 Mar 2028
NCT05104476 A Study of Lu AF82422 in Participants With Multiple System Atrophy Phase Two Active Nov 2021 Mar 2028
NCT05167721 Stem cells Phase Two Active Dec 2021 Dec 2026
NCT06120049 PET vs SPECT (Single-Photon Emission Computed Tomography) Phase Two Active Recruiting Jan 2024 Jul 2026
NCT06162013 NAD Replenishment Therapy Phase Two Active Recruiting Mar 2024 Dec 2028
NCT06868628 A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (M… Phase Two Active Recruiting May 2025 Apr 2027
NCT07465198 Autologous Stem Cell Therapy in Patients With Multiple System Atrophy Phase Two Active Not Yet Recruiting Sep 2026 Mar 2031
NCT02897063 Midodrine and Droxidopa Phase One Active Recruiting Sep 2016 Dec 2026
NCT04620382 Midodrine vs Abdominal Compression Phase One Active Recruiting Nov 2020 Dec 2025
NCT05698017 Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for … Phase One Active Nov 2022 Feb 2026
NCT06098612 PET (Positron Emission Tomography) Phase One Active Recruiting May 2024 Nov 2027
NCT06671236 Regulatory T Cells (NP001 Cell Injection) Phase One Active Recruiting Nov 2024 Dec 2027
NCT06683365 Sural Nerve Grafting Phase One Active Recruiting Feb 2025 Dec 2030
NCT06891703 [18F]ACI-15916 PET in α-synucleinopathies Phase One Active Recruiting Mar 2025 Mar 2026
NCT06765733 The Study of Safety and Preliminary Efficacy of Aleeto in Patients with MSA Phase One Active Recruiting May 2025 Dec 2026
NCT06607900 hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases Phase One Active Not Yet Recruiting Jul 2025 Aug 2028
NCT06831500 Feasibility of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in MSA Phase One Active Recruiting Jul 2025 Nov 2026
NCT07289477 A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple Syst… Phase One Active Recruiting Jan 2026 Jul 2031
NCT07476352 Expansion Study of ALT001 in Patients With Multiple System Atrophy Phase One Active Not Yet Recruiting May 2026 Oct 2027
NCT05696717

Ampreloxetine

Phase: Phase Three
Status: Active
Start: Jun 2023  |  Completion: Jan 2028
NCT06706622

Lu AF82422

Phase: Phase Three
Status: Active
Start: Dec 2024  |  Completion: Oct 2029
NCT05923866

ONO-2808

Phase: Phase Two
Status: Active
Start: Sep 2023  |  Completion: Jan 2027
NCT06568237

TEV-56286

Phase: Phase Two
Status: Active Recruiting
Start: Oct 2024  |  Completion: Sep 2027
NCT06671938

Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With MSA

Phase: Phase Two
Status: Active
Start: Oct 2024  |  Completion: Aug 2026
NCT06848231

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Phase: Phase Two
Status: Active Recruiting
Start: Mar 2025  |  Completion: Dec 2026
NCT07197866

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Phase: Phase Two
Status: Active Recruiting
Start: Sep 2025  |  Completion: May 2029
NCT03482297

Abdominal Binder

Phase: Phase One
Status: Active Recruiting
Start: Mar 2018  |  Completion: Dec 2024
NCT04165486

ION464

Phase: Phase One
Status: Active Recruiting
Start: Jul 2022  |  Completion: Sep 2027
NCT04680065

GDNF Gene Therapy

Phase: Phase One
Status: Active
Start: Oct 2023  |  Completion: Aug 2028
NCT07446894

Phase III Trial of MSA-01 in Multiple System Atrophy

Phase: Phase Three
Status: Active Recruiting
Start: Feb 2026  |  Completion: Mar 2028
NCT05104476

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Phase: Phase Two
Status: Active
Start: Nov 2021  |  Completion: Mar 2028
NCT05167721

Stem cells

Phase: Phase Two
Status: Active
Start: Dec 2021  |  Completion: Dec 2026
NCT06120049

PET vs SPECT (Single-Photon Emission Computed Tomography)

Phase: Phase Two
Status: Active Recruiting
Start: Jan 2024  |  Completion: Jul 2026
NCT06162013

NAD Replenishment Therapy

Phase: Phase Two
Status: Active Recruiting
Start: Mar 2024  |  Completion: Dec 2028
NCT06868628

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Phase: Phase Two
Status: Active Recruiting
Start: May 2025  |  Completion: Apr 2027
NCT07465198

Autologous Stem Cell Therapy in Patients With Multiple System Atrophy

Phase: Phase Two
Status: Active Not Yet Recruiting
Start: Sep 2026  |  Completion: Mar 2031
NCT02897063

Midodrine and Droxidopa

Phase: Phase One
Status: Active Recruiting
Start: Sep 2016  |  Completion: Dec 2026
NCT04620382

Midodrine vs Abdominal Compression

Phase: Phase One
Status: Active Recruiting
Start: Nov 2020  |  Completion: Dec 2025
NCT05698017

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early t…

Phase: Phase One
Status: Active
Start: Nov 2022  |  Completion: Feb 2026
NCT06098612

PET (Positron Emission Tomography)

Phase: Phase One
Status: Active Recruiting
Start: May 2024  |  Completion: Nov 2027
NCT06671236

Regulatory T Cells (NP001 Cell Injection)

Phase: Phase One
Status: Active Recruiting
Start: Nov 2024  |  Completion: Dec 2027
NCT06683365

Sural Nerve Grafting

Phase: Phase One
Status: Active Recruiting
Start: Feb 2025  |  Completion: Dec 2030
NCT06891703

[18F]ACI-15916 PET in α-synucleinopathies

Phase: Phase One
Status: Active Recruiting
Start: Mar 2025  |  Completion: Mar 2026
NCT06765733

The Study of Safety and Preliminary Efficacy of Aleeto in Patients with MSA

Phase: Phase One
Status: Active Recruiting
Start: May 2025  |  Completion: Dec 2026
NCT06607900

hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

Phase: Phase One
Status: Active Not Yet Recruiting
Start: Jul 2025  |  Completion: Aug 2028
NCT06831500

Feasibility of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in MSA

Phase: Phase One
Status: Active Recruiting
Start: Jul 2025  |  Completion: Nov 2026
NCT07289477

A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy

Phase: Phase One
Status: Active Recruiting
Start: Jan 2026  |  Completion: Jul 2031
NCT07476352

Expansion Study of ALT001 in Patients With Multiple System Atrophy

Phase: Phase One
Status: Active Not Yet Recruiting
Start: May 2026  |  Completion: Oct 2027

Tracker extracts data from ClinicalTrials.gov, a database managed by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in Bethesda, Maryland. This trial tracker is provided for informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider for all diagnosis questions or medical treatment before taking any action or making any decision regarding your health.

Understanding Clinical Trial Phases:

Phase 1: A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.

Phase 2: A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

Phase 3: A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Phase 4: A phase of research to describe clinical trials occurring after the FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use.

Phase Not Applicable: Describes trials without FDA-defined phases, including trials of devices or behavioral interventions.

Understanding the Status of active studies:

Not yet recruiting: The study has not started recruiting participants.

Recruiting: The study is currently recruiting participants.

Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.